What’s the latest news on ibrutinib/ibrutinib prices in 2025

Ibrutinib/Ibrutinib (Ibrutinib), as the first approved Bruton's tyrosine kinase (BTK) inhibitor, has played an important role in the treatment of hematological tumors since its launch. Its application scope covers chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) and graft-versus-host disease (cGVHD), etc.

In the domestic market, ibrutinib has been officially launched and included in the national medical insurance directory. Taking 140mg*90 capsules as an example, the current market price is about more than 10,000 yuan. Compared with the cost before medical insurance, the financial burden on patients is greatly reduced. The implementation of the medical insurance reimbursement policy not only improves the accessibility of drugs, but also allows more patients with hematological tumors to adhere to long-term standardized medication. At the same time, the common specifications in the domestic market are mostly concentrated in 140mg capsule packaging to meet the needs of different treatment options.

In contrast, the selling price of ibrutinib in overseas markets is significantly higher. For example, the price of drugs of the same specifications in the United States may exceed US$10,000, which to a certain extent has prompted some countries to accelerate the development and marketing of generic drugs. At present, India, Laos and other countries have produced and sold ibrutinib generic drugs in multiple specifications, such as 140 mg 120 pills, 140 mg 112 pills, etc. Among them, the version produced by Lucius Pharmaceutical Factory in Laos is the most common, and the price per box is only more than 1,000 yuan. Although these generic drugs are consistent with the original drugs in terms of ingredients and dosage design, attention still needs to be paid to their sources and supervision during clinical use.

From the overall trend, with the intensification of competition for BTK inhibitors globally and the continued advancement of domestic medical insurance negotiations, the price of ibrutinib is expected to decline further. For patients, this not only means more channels for obtaining drugs, but also the ability to choose more cost-effective treatment options under the guidance of doctors.

Reference materials:https://www.imbruvica.com/